Condition
Lymphocytes
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Withdrawn1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06047977Phase 1RecruitingPrimary
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
NCT05506748Completed
Association Between Preoperative HALP and Immediate Postoperative Outcomes
NCT03336086Phase 3CompletedPrimary
Effect of Weight Reduction on Immunity
NCT00514982Phase 2Withdrawn
Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome
Showing all 4 trials